

Annelies Cannnaert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6536851/publications.pdf>

Version: 2024-02-01

34
papers

1,114
citations

430874

18
h-index

414414

32
g-index

35
all docs

35
docs citations

35
times ranked

677
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay. <i>Analytical Chemistry</i> , 2016, 88, 11476-11485.	6.5	193
2	Activity-Based Detection of Consumption of Synthetic Cannabinoids in Authentic Urine Samples Using a Stable Cannabinoid Reporter System. <i>Analytical Chemistry</i> , 2017, 89, 9527-9536.	6.5	81
3	Report on a novel emerging class of highly potent benzimidazole NPS opioids: Chemical and in vitro functional characterization of isotonitazene. <i>Drug Testing and Analysis</i> , 2020, 12, 422-430.	2.6	65
4	Synthesis and <i>in Vitro</i> Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA. <i>ACS Chemical Neuroscience</i> , 2020, 11, 4434-4446.	3.5	62
5	Application of an activity-based receptor bioassay to investigate the in vitro activity of selected indole- and indazole-carboxamide-based synthetic cannabinoids at CB1 and CB2 receptors. <i>Drug Testing and Analysis</i> , 2019, 11, 501-511.	2.6	61
6	Enantiospecific Synthesis, Chiral Separation, and Biological Activity of Four Indazole-3-Carboxamide-Type Synthetic Cannabinoid Receptor Agonists and Their Detection in Seized Drug Samples. <i>Frontiers in Chemistry</i> , 2019, 7, 321.	3.6	48
7	Activity-Based Concept to Screen Biological Matrices for Opiates and (Synthetic) Opioids. <i>Clinical Chemistry</i> , 2018, 64, 1221-1229.	3.2	46
8	Activity-Based Detection of Cannabinoids in Serum and Plasma Samples. <i>Clinical Chemistry</i> , 2018, 64, 918-926.	3.2	44
9	The next generation of synthetic cannabinoids: Detection, activity, and potential toxicity of pent-4en and but-3en analogues including MDMB-4en-PINACA. <i>Drug Testing and Analysis</i> , 2021, 13, 427-438.	2.6	38
10	Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L-valine or L-tert-leucine. <i>Drug Testing and Analysis</i> , 2019, 11, 1183-1191.	2.6	37
11	In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances. <i>Archives of Toxicology</i> , 2020, 94, 3819-3830.	4.2	36
12	Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform. <i>Biochemical Pharmacology</i> , 2020, 177, 113910.	4.4	36
13	Molecular dissection of the human A3 adenosine receptor coupling with β -arrestin2. <i>Biochemical Pharmacology</i> , 2018, 148, 298-307.	4.4	34
14	First Report on Brorphine: The Next Opioid on the Deadly New Psychoactive Substance Horizon?. <i>Journal of Analytical Toxicology</i> , 2021, 44, 937-946.	2.8	31
15	Shape matters: The application of activity-based <i>in vitro</i> bioassays and chiral profiling to the pharmacological evaluation of synthetic cannabinoid receptor agonists in drug-infused papers seized in prisons. <i>Drug Testing and Analysis</i> , 2021, 13, 628-643.	2.6	28
16	Activity-Based Detection and Bioanalytical Confirmation of a Fatal Carfentanil Intoxication. <i>Frontiers in Pharmacology</i> , 2018, 9, 486.	3.5	27
17	Comprehensive investigation on synthetic cannabinoids: Metabolic behavior and potency testing, using 5F-APP-PICA and AMB-FUBINACA as model compounds. <i>Drug Testing and Analysis</i> , 2019, 11, 1358-1368.	2.6	24
18	In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β -arrestin 2 recruitment to the serotonin 2A receptor. <i>Archives of Toxicology</i> , 2020, 94, 3449-3460.	4.2	21

#	ARTICLE	IF	CITATIONS
19	Diagnosing intake and rationalizing toxicities associated with 5F-MDMB-PINACA and 4F-MDMB-BINACA abuse. <i>Archives of Toxicology</i> , 2021, 95, 489-508.	4.2	20
20	Toxicokinetics and toxicodynamics of the fentanyl homologs cyclopropanoyl-1-benzyl-4- <i>Å</i> -fluoro-4-anilinopiperidine and furanoyl-1-benzyl-4-anilinopiperidine. <i>Archives of Toxicology</i> , 2020, 94, 2009-2025.	4.2	19
21	Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB ₁ receptor activation assays: Part I- Synthesis, analytical characterization, and binding affinity for human CB ₁ receptors. <i>Drug Testing and Analysis</i> , 2021, 13, 1392-1401.	2.6	19
22	Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB ₁ receptor activation assays- Part II: Structure activity relationship assessment via a β -arrestin recruitment assay. <i>Drug Testing and Analysis</i> , 2021, 13, 1402-1411.	2.6	18
23	Setup of a Serotonin 2A Receptor (5-HT _{2A}) Bioassay: Demonstration of Its Applicability To Functionally Characterize Hallucinogenic New Psychoactive Substances and an Explanation Why 5-HT _{2A} Bioassays Are Not Suited for Universal Activity-Based Screening of Biofluids for New Psychoactive Substances. <i>Analytical Chemistry</i> , 2019, 91, 15444-15452.	6.5	16
24	Activity-based reporter assays for the screening of abused substances in biological matrices. <i>Critical Reviews in Toxicology</i> , 2019, 49, 95-109.	3.9	16
25	<i>In vitro</i> activity profiling of Cumyl-PEGACLONE variants at the CB ₁ receptor: Fluorination versus isomer exploration. <i>Drug Testing and Analysis</i> , 2020, 12, 1336-1343.	2.6	16
26	Hide and Seek: Overcoming the Masking Effect of Opioid Antagonists in Activity-Based Screening Tests. <i>Clinical Chemistry</i> , 2019, 65, 1604-1605.	3.2	15
27	Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB ₁ receptor activation assays. Part III: The G protein pathway and critical comparison of different assays. <i>Drug Testing and Analysis</i> , 2021, 13, 1412-1429.	2.6	14
28	Validation of Activity-Based Screening for Synthetic Cannabinoid Receptor Agonists in a Large Set of Serum Samples. <i>Clinical Chemistry</i> , 2019, 65, 347-349.	3.2	13
29	Report on a New Opioid NPS: Chemical and <i>In Vitro</i> Functional Characterization of a Structural Isomer of the MT-45 Derivative Diphenipenol. <i>Journal of Analytical Toxicology</i> , 2021, 45, 134-140.	2.8	12
30	NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?. <i>ACS Chemical Neuroscience</i> , 2021, 12, 4020-4036.	3.5	7
31	Evidence of enzyme-mediated transesterification of synthetic cannabinoids with ethanol: potential toxicological impact. <i>Forensic Toxicology</i> , 2020, 38, 95-107.	2.4	5
32	Semiquantitative Activity-Based Detection of JWH-018, a Synthetic Cannabinoid Receptor Agonist, in Oral Fluid after Vaping. <i>Analytical Chemistry</i> , 2020, 92, 6065-6071.	6.5	5
33	Machine Learning to Assist in Large-Scale, Activity-Based Synthetic Cannabinoid Receptor Agonist Screening of Serum Samples. <i>Clinical Chemistry</i> , 2022, 68, 906-916.	3.2	5
34	Are the N-desmethylated metabolites of U-47700 more active than their parent compound? <i>In vitro</i> opioid receptor activation of N-desmethyl-U-47700 and N,N-bisdesmethyl-U-47700. <i>Drug Testing and Analysis</i> , 2021, . .	2.6	2